Segregation analysis from large international consortia has been used to calculate ovarian cancer risks in RAD51C, RAD51D, and PALB2, and could be applied to other moderate risk ovarian cancer genes [10,12]. The gene discussed is RAD51D; the disease is ovarian cancer.